- Report
- October 2024
- 182 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- November 2024
- 150 Pages
Global
From €4611EUR$4,850USD£3,873GBP
- Report
- July 2024
- 231 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- May 2024
- 185 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- October 2023
- 85 Pages
United States
From €4611EUR$4,850USD£3,873GBP
- Report
- May 2022
- 196 Pages
Global
From €2495EUR$2,625USD£2,096GBP
€4991EUR$5,250USD£4,193GBP
- Drug Pipelines
- February 2022
- 114 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- August 2022
- 111 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- June 2023
- 112 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- October 2022
- 82 Pages
Global
From €3323EUR$3,495USD£2,791GBP
- Report
- October 2019
- 128 Pages
Global
From €14255EUR$14,995USD£11,976GBP
- Report
- October 2024
- 83 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- October 2022
- 145 Pages
Global
From €1901EUR$2,000USD£1,597GBP

Axial Spondyloarthritis (axSpA) is a type of inflammatory arthritis that affects the spine and sacroiliac joints. It is a chronic, progressive condition that can cause pain, stiffness, and swelling in the affected areas. Immune Disorders Drugs are used to treat axSpA, as they help to reduce inflammation and pain. These drugs can be taken orally, injected, or infused, depending on the severity of the condition. Commonly used drugs include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), biologic agents, and corticosteroids.
The Axial Spondyloarthritis Drug market is a rapidly growing segment of the Immune Disorders Drugs market. It is driven by the increasing prevalence of axSpA, as well as the development of new drugs and treatments. Companies in the market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB. Show Less Read more